We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Commissioner Stephen Hahn said Friday that the agency will resume domestic inspections this month using a new risk assessment system developed in response to the pandemic. Read More
The FDA issued a warning letter to active pharmaceutical ingredient (API) manufacturer Vega Life Sciences for violations of good manufacturing practices (cGMP) at its facility in southern India. Read More
The FDA cited Takeda biotech subsidiary Baxalta for a host of violations at its Thousand Oaks, California facility, including GMP lapses that could lead to product contamination. Read More
The FDA hit a La Habra, California compounding pharmacy with a warning letter for repeated violations, including dirty equipment and the presence of insects. Read More
Canadian sterile drug manufacturer Viatrexx was hit with an FDA warning letter for serious violations of aseptic practices observed during an agency inspection. Read More
Cosmaceutical Research Lab was hit with an FDA warning letter for serious violations uncovered during an inspection of the firm’s manufacturing facility in British Columbia, Canada. Read More
The FDA hit Tokyo-based drugmaker Takeda with a warning letter after an inspection revealed that manufacturing problems for its drug Natpara (parathyroid hormone) uncovered last year were still not resolved. Read More